Cargando…
Choosing a Second Biologic Agent for Inflammatory Bowel Disease Patients—Cost Considerations and Clinical Outcomes
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802441/ https://www.ncbi.nlm.nih.gov/pubmed/36777295 http://dx.doi.org/10.1093/crocol/otaa032 |
| _version_ | 1784861682726600704 |
|---|---|
| author | Clarke, Kofi |
| author_facet | Clarke, Kofi |
| author_sort | Clarke, Kofi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9802441 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-98024412023-02-10 Choosing a Second Biologic Agent for Inflammatory Bowel Disease Patients—Cost Considerations and Clinical Outcomes Clarke, Kofi Crohns Colitis 360 Editorial Oxford University Press 2020-04-29 /pmc/articles/PMC9802441/ /pubmed/36777295 http://dx.doi.org/10.1093/crocol/otaa032 Text en © 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Editorial Clarke, Kofi Choosing a Second Biologic Agent for Inflammatory Bowel Disease Patients—Cost Considerations and Clinical Outcomes |
| title | Choosing a Second Biologic Agent for Inflammatory Bowel Disease Patients—Cost Considerations and Clinical Outcomes |
| title_full | Choosing a Second Biologic Agent for Inflammatory Bowel Disease Patients—Cost Considerations and Clinical Outcomes |
| title_fullStr | Choosing a Second Biologic Agent for Inflammatory Bowel Disease Patients—Cost Considerations and Clinical Outcomes |
| title_full_unstemmed | Choosing a Second Biologic Agent for Inflammatory Bowel Disease Patients—Cost Considerations and Clinical Outcomes |
| title_short | Choosing a Second Biologic Agent for Inflammatory Bowel Disease Patients—Cost Considerations and Clinical Outcomes |
| title_sort | choosing a second biologic agent for inflammatory bowel disease patients—cost considerations and clinical outcomes |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802441/ https://www.ncbi.nlm.nih.gov/pubmed/36777295 http://dx.doi.org/10.1093/crocol/otaa032 |
| work_keys_str_mv | AT clarkekofi choosingasecondbiologicagentforinflammatoryboweldiseasepatientscostconsiderationsandclinicaloutcomes |